A double-blind, placebo-controlled crossover study was undertaken to assess the efficacy and tolerability of
sumatriptan in patients with atypical
facial pain. Patients were aged 18-65 years and had at least a 6 months history of atypical
facial pain. A total of 19 patients were recruited and assessed for
pain scores (total, sensory and affective) by using a short form McGill
pain questionnaire preinjection and and at 60 and 120 minutes after
subcutaneous injection of
sumatriptan (6 mg) or placebo. Safety and tolerability was assessed by recording adverse events during and after the injection. One patient received only one treatment since her
pain symptoms resolved after the first treatment. Rest of the patients returned to the clinic 3-6 weeks later and received alternate treatment for atypical
facial pain in the same fashion as on the first occasion. Treatment of patients with
sumatriptan produced significant relief in sensory, affective and total
pain at 120 minutes postinjection (P < .05).
Sumatriptan failed to produce a significant reduction in sensory and total
pain scores at 60 minutes following treatment, however the result was statistically significant for the affective
pain score (P < .05). No death or other serious adverse events were reported. No patient was withdrawn from the study due to an adverse event. However, all the patients treated with
sumatriptan experienced one or more adverse events. The most common reported adverse symptoms during the
sumatriptan treatment period were
injection site reactions,
headache, feeling of heaviness, warm or hot sensation and disorders of mouth or tongue. However, most of these side effects were mild and transient. In conclusion, this study points towards some beneficial effect of a single
subcutaneous injection of
sumatriptan in the treatment of atypical
facial pain. However, this data is not sufficient to suggest the clinical utility of subcutaneous
sumatriptan (6 mg) for the management of atypical
facial pain. Further studies are necessary to test the effects of prolonged subcutaneous and oral multiple dose administration of
sumatriptan for the treatment of atypical
facial pain.